Epidemiology
A fibroblastic tumor of infants and young children, often congenital or diagnosed during the first year of life; the WHO 2020 classification places it among intermediate (rarely metastasizing) tumors. In infants it can grow considerably but respond to targeted treatment if an NTRK fusion is confirmed.
Basic features
It can grow quickly and ulcerate or affect function, but it usually has more favorable biology than adult fibrosarcomas.
Usual treatment
Management aims to preserve function: most cases carry the ETV6-NTRK3 fusion and, when an NTRK fusion is confirmed, TRK inhibitors (larotrectinib, entrectinib) achieve marked responses that allow the tumor to be shrunk and avoid amputations, very extensive resections or intensive chemotherapy; conservative surgery and chemotherapy are used depending on the case.
Outcomes and prognosis
Survival in localized disease is very good, and targeted therapies against the NTRK fusion have improved control; pediatric follow-up monitors function and recurrence.
